fda tirzepatide shortage resolved 2025 Resolved: What It Means for Your Weight Loss Journey fda deadline for compounded semaglutide

None of these compounds are approved by Health Canada for general therapeutic use they operate in various specific contexts

Diabetes is a chronic disease that progresses over decades

Just for the convenience of all of u, I am adding the list the I recently posted just a few days back here on LinkedIn

--- Sources Neeland et al., Changes in lean body mass with GLP-1-based therapies and mitigation strategies , Diabetes, Obesity and Metabolism (2024): Jensterle et al., Rethinking Muscle Health Assessment in GLP-1-Based Therapies for Obesity: Beyond Lean Mass , DOM (2026): Wilding et al., STEP 1 body composition exploratory analysis: LEAN-PREP randomised controlled trial protocol (2025): Function and Lean Mass Preservation With Resistance Exercise During GLP-1RA Treatment, ClinicalTrials.gov: WHO Guidelines on Physical Activity and Sedentary Behaviour: Wegovy Singapore availability and prescription status:

Tirzepatides engineered backbone activates both pathways concurrently, producing compounded effects on insulin sensitivity and glucose-dependent insulin secretion that neither agonist achieves independently

#ObesityMedicine #MetabolicHealth #PrecisionMedicine #Endocrinology #GLP1 #Tirzepatide #Semaglutide #BariatricSurgery #ChronicDisease #HealthcareInnovation #LifestyleMedicine To view or add a comment, sign in OBESITY NEWS Recent press release by Novo Nordisk highlights interesting points CHRONIC DISEASE Obesity should be approached as a chronic, progressive, and multifactorial disease, not as a matter of willpower